Shares of Chimerix Inc. (NASDAQ:CMRX) were up 6.8% during trading on Wednesday . The company traded as high as $4.23 and last traded at $4.23, with a volume of 746,454 shares. The stock had previously closed at $3.96.

A number of analysts have recently commented on CMRX shares. Zacks Investment Research upgraded shares of Chimerix from a “hold” rating to a “buy” rating and set a $5.25 price target for the company in a research note on Wednesday, May 11th. FBR & Co reiterated a “hold” rating on shares of Chimerix in a research note on Sunday, July 17th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. Chimerix has an average rating of “Hold” and a consensus target price of $16.98.

The firm’s 50-day moving average is $3.93 and its 200 day moving average is $5.26. The stock’s market cap is $195.48 million.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.09. The company had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $2.79 million. On average, analysts forecast that Chimerix Inc. will post ($2.06) EPS for the current fiscal year.

In related news, CEO M Michelle Berrey purchased 13,188 shares of Chimerix stock in a transaction dated Friday, June 24th. The shares were acquired at an average price of $3.69 per share, for a total transaction of $48,663.72. Following the acquisition, the chief executive officer now directly owns 258,821 shares in the company, valued at $955,049.49. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Ernest Mario purchased 25,000 shares of Chimerix stock in a transaction dated Wednesday, May 11th. The shares were bought at an average price of $4.85 per share, for a total transaction of $121,250.00. Following the acquisition, the director now owns 297,240 shares in the company, valued at $1,441,614. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Jennison Associates LLC increased its stake in Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned about 2.76% of Chimerix worth $11,400,000 at the end of the most recent quarter.

Chimerix, Inc a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company’s lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.